The evidence that a Poly(ADP-ribose)polymerase (PARP) inhibitor provided clinical benefit to patients carrying breast-cancer-associated BRCA1 or BRCA2 gene mutations was a breakthrough in cancer therapy [1] and boosted the initiation of clinical trials involving several other PARP inhibitors. This evidence concerns the gene PARP1 and breast carcinoma.